Dont take any stated yields for granted these days! The financial news has been flooded with dividend cuts lately, with Teva Pharmaceutical (TEVA) and Mattel (MAT) taking the hatchet to their payouts, and telecom Windstream (WIN) dropping its dividend too.
Its dangerous to buy headline yields or even supposedly safe blue chips with more modest dividends without looking at the profits funding these payouts. Companies with high payout ratios (how much in earnings, funds from operations and other measures a company pays out in the form of dividends) are a twofold risk:
High payout ratios can lead to a slowing in dividend growth, which means your payout is increasingly likely to fall behind inflation.
Hot Blue Chip Stocks To Watch For 2018: Baytex Energy Corp(BTE)
- [By Max Byerly]
Baytex Energy (NYSE: BTE) and Pioneer Energy Services (NYSE:PES) are both small-cap oils/energy companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.
- [By Logan Wallace]
Baytex Energy (TSE:BTE) (NYSE:BTE) had its price target raised by equities researchers at TD Securities from C$4.50 to C$5.50 in a report issued on Friday. The brokerage currently has a “hold” rating on the stock. TD Securities’ price target points to a potential downside of 0.90% from the company’s current price.
Hot Blue Chip Stocks To Watch For 2018: Paylocity Holding Corporation(PCTY)
- [By Brian Feroldi]
Lately, on Industry Focus: Tech, we’ve focused on the megacap businesses that have been dominating the news — at the cost of shedding some light on smaller companies with massive growth potential. In this week’s episode, host Dylan Lewis talks with Fool.com contributorBrian Feroldi about three ultra-compelling small-cap tech companies: HubSpot (NYSE:HUBS), AppFolio (NASDAQ:APPF), and Paylocity (NASDAQ:PCTY).
- [By Benzinga News Desk]
The curtain could come down any day on MoviePass’ bumpy run as an independent company: Link
Chicago Fed national activity index +0.10 vs +0.27 expected
The Composite Purchasing Managers' Index for April will be released at 9:45 a.m. ET.
Existing home sales report for March is schedule for release at 10:00 a.m. ET.
The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET.
Deutsche Bank upgraded Michael Kors (NYSE: KORS) from Hold to Buy
RBC downgraded Paylocity (NASDAQ: PCTY) from Outperform to Sector Perform
Suntrust downgraded Oasis Petroleum (NYSE: OAS) from Hold to Sell
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.
- [By Logan Wallace]
Paylocity Holding (NASDAQ:PCTY) CEO Steven R. Beauchamp sold 80,000 shares of the business’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $55.37, for a total value of $4,429,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
- [By Motley Fool Staff]
Paylocity (NASDAQ:PCTY) is looking to change all of that. The company’s cloud-based platform was built from the ground up to provide users with an easy-to-use, mobile-focused solution. Paylocity has been grabbing market share away from the industry giants ever since.
Hot Blue Chip Stocks To Watch For 2018: Telefonica SA(TEF)
- [By Max Byerly]
BME:TEF traded up €0.15 ($0.19) during midday trading on Friday, reaching €8.20 ($10.12). 33,480,000 shares of the stock traded hands, compared to its average volume of 23,390,000. Telef?nica has a 12 month low of €7.45 ($9.20) and a 12 month high of €10.63 ($13.12).
ILLEGAL ACTIVITY NOTICE: “Telef?nica (TEF) Receives €9.69 Consensus PT from Brokerages” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3380340/telef%ef%bf%bdnica-tef-receives-9-69-consensus-pt-from-brokerages.html.
Hot Blue Chip Stocks To Watch For 2018: Ultragenyx Pharmaceutical Inc.(RARE)
- [By Todd Campbell]
A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that’s successfully developed drugs for rare diseases.
- [By Chris Lange]
Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.
- [By Joseph Griffin]
BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.
A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.
Hot Blue Chip Stocks To Watch For 2018: SPDR Blmbg Barclays Intl Trs Bd ETF (BWX)
- [By Ethan Ryder]
Spdr Bloomberg Barclays International Treasury Bond Etf (BMV:BWX) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 98,671 shares, a decline of 86.0% from the April 13th total of 706,330 shares. Based on an average daily volume of 636,403 shares, the days-to-cover ratio is currently 0.2 days.